Full Event Guide
Talks from 19+ industry leaders who are pioneering peptide drug conjugates, oligonucleotide drug conjugates, fragment drug conjugates, bispecific drug conjugates, degrader conjugates, radio conjugates, and more. Â
Discussion-based workshops covering the challenges that accompany developing first-in-class conjugates and the linker chemistry considerations when working with novel payloads.
6 hours of dedicated networking time to build strong relationships with industry leaders, researchers, and potential investors to overcome challenges and accelerate development of novel conjugate drugs.Â
A panel discussion to gain first hand insights from successful biotech companies and experienced investors on navigating the funding landscape, understand investor expectations, and effectively present projects to secure funding.Â
